Skip to main content

View full-text article in PMC

. 2010 Oct 1;103(10):403–411. doi: 10.1258/jrsm.2010.090441

Table 2.

Risk of mortality associated with antipyretic treatment in individual studies

Study		Mortality/Total (%)		OR (95% CI)
				OR (95% CI)
Number	Reference	Antipyretic	Control
1	Crocker et al.¹⁹	70/155(45.2)	33/98(33.6)	1.6(1.0–2.7)
2	Crocker et al.¹⁹	32/114(28.1)	19/74(25.7)	1.1(0.6–2.2)
3	Davis et al.²⁰	40/61(65.6)	32/60(53.3)	1.7(0.8–3.4)
4	Davis et al.²⁰	12/30(40.0)	12/25(48.0)	0.7(0.3–2.1)
5	Sunden et al.²¹	3/16(16.7)	0/4(0)	4.0(0.2–80.5)
6	Sunden et al.²¹	4/24(16.7)	0/6(0)	4.0(0.3–53.6)
7	Crocker et al.¹⁹	80/149(53.7)	36/88(40.9)	1.7(1.0–2.8)
8	Crocker et al.¹⁹	50/148(33.8)	24/64(37.5)	0.9(0.5–1.6)